Myelodysplastic syndromes: moving towards personalized management
Open Access
- 1 July 2020
- journal article
- review article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 105 (7) , 1765-1779
Abstract
The myelodysplastic syndromes (MDS) share their origin in the hematopoietic stem cell but have otherwise very heterogeneous biological and genetic characteristics. Clinical features are dominated by cytopenia and a substantial risk for progression to acute myeloid leukemia. According to the World Health Organization, MDS is defined by cytopenia, bone marrow dysplasia and certain karyotypic abnormalities. The understanding of disease pathogenesis has undergone major development with the implementation of next-generation sequencing and a closer integration of morphology, cytogenetics and molecular genetics is currently paving the way for improved classification and prognostication. True precision medicine is still in the future for MDS and the development of novel therapeutic compounds with a propensity to markedly change patients’ outcome lags behind that for many other blood cancers. Treatment of higher-risk MDS is dominated by monotherapy with hypomethylating agents but novel combinations are currently being evaluated in clinical trials. Agents that stimulate erythropoiesis continue to be first-line treatment for the anemia of lower-risk MDS but luspatercept has shown promise as second-line therapy for sideroblastic MDS and lenalidomide is an established second-line treatment for del(5q) lower-risk MDS. The only potentially curative option for MDS is hematopoietic stem cell transplantation, until recently associated with a relatively high risk of transplant-related mortality and relapse. However, recent studies show increased cure rates due to better tools to target the malignant clone with less toxicity. This review provides a comprehensive overview of the current status of the clinical evaluation, biology and therapeutic interventions for this spectrum of disorders.Keywords
This publication has 200 references indexed in Scilit:
- Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blastsBlood, 2011
- SomaticSF3B1Mutation in Myelodysplasia with Ring SideroblastsNew England Journal of Medicine, 2011
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesNew England Journal of Medicine, 2011
- Stochastic epigenetic variation as a driving force of development, evolutionary adaptation, and diseaseProceedings of the National Academy of Sciences, 2010
- Telomere DiseasesNew England Journal of Medicine, 2009
- Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDSBlood, 2008
- New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patientsBlood, 2007
- A Microenvironment-Induced Myeloproliferative Syndrome Caused by Retinoic Acid Receptor γ DeficiencyCell, 2007
- A DNA damage checkpoint response in telomere-initiated senescenceNature, 2003
- Live or let die: the cell's response to p53Nature Reviews Cancer, 2002